This relatively high mutation rate of EGFR in CRC may present itself as an opportunity for the use of the non-small cell lung carcinoma tyrosine kinase inhibitors (TKIs) treatment regimes targeting this receptor. This evidence concerns the gene EGFR and non-small cell lung carcinoma.